Organization | HRYZ Biotech Co.

HRYZ Biotech Co. Report issue

For profit Phase 1

Founded: ShenZhen China (2013)

Status: Defunct (2019)

Organization Overview

First Clinical Trial

2017

NCT03034304

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

HRYZ Biotech Co.

Active Ingredients

Drugs in Phase 1 Trials (6)

cyclophosphamide (cytoxan) (2 trials)

dendritic cells loaded with 17 antigens (1 trial)

fludarabine (fludara) (2 trials)

hryz-t101 (2 trials)

ifosfamide (ifex) (1 trial)

masct:multiple antigens specific cellular therapy (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Sarcoma (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 4
# of Trial APIs: 6